Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Icecure Medical ( (ICCM) ) just unveiled an update.
On December 10, 2025, IceCure Medical announced that its ProSense® Cryoablation technology was featured in four independent studies presented at the Radiological Society of North America’s Annual Meeting, held from November 30 to December 4, 2025. These studies, involving 263 patients, highlight the growing adoption and effectiveness of ProSense® in treating breast cancer, particularly as a non-surgical option for patients not suitable for surgery. The presentation of these studies at such a prestigious global platform underscores the increasing recognition of IceCure’s technology within the medical community, following recent FDA marketing approval for low-risk breast cancer treatment.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor destruction, focusing primarily on breast, kidney, bone, and lung cancers. The company’s flagship product, ProSense®, offers a minimally invasive alternative to surgical tumor removal and is marketed globally in regions including the U.S., Europe, and Asia.
Average Trading Volume: 1,171,582
Technical Sentiment Signal: Sell
Current Market Cap: $47.01M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.